DAIICHI-SANKYO
10.7.2024 12:07:31 CEST | Business Wire | Press release
Daiichi Sankyo (TSE: 4568) today announced that it has opened a new affiliate for its oncology business in Athens, Greece. The establishment highlights the company’s strong commitment to addressing treatment needs of people living with cancer in the European region. Thomais Konstantopoulou has been appointed Country Manager, Daiichi Sankyo Greece Single Member S.A.
“We are very happy to open yet another new affiliate in Europe to bring our innovative medicines to patients who can benefit from them. To have representation in a country is the best way of doing this,” said Thomais Konstantopoulou, Country Manager, Daiichi Sankyo Greece. “Our decision to establish a presence in Greece stems from our deep-rooted commitment to serving as many patients with cancer as possible with our innovative portfolio, aiming to improve outcomes and quality of life. It also is linked to a continuous effort of multiple stakeholders that elevates oncology in the country’s healthcare agenda and promotes active dialogue. Daiichi Sankyo is investing in Greece, which aligns with the country’s ambition to create conditions that foster innovation, talent retention, technology advancement and economic growth. We are focused on advancing meaningful innovation and creating jobs in a sustainable manner.”
Daiichi Sankyo has affiliates in 14 European countries, alongside representations in Norway, Finland, Sweden and Luxembourg. Europe has always been a focus for the company’s medicines, as well as a key region for continuous investment. With 20 research and development sites across 12 countries, Daiichi Sankyo utilizes a global network to drive innovation. Currently, the company is focused on developing antibody drug conjugates (ADCs), which are targeted cancer medicines that combine target-specificity and anti-tumor activity in a single molecule.
“From pursuing new medicines and new methods of drug discovery and delivery to achieving excellence throughout our organization by continuously examining new ideas, innovation is paramount for all we do,” said Dr. Dimitrios Krikelis, Head of Medical Affairs, Daiichi Sankyo Greece. “Even before the establishment of the Greek affiliate, Daiichi Sankyo has been partnering with the local oncology community through our clinical development program. We are fortunate to have physicians with a wealth of clinical expertise and a vibrant research community in Greece.”
Daiichi Sankyo aims to be an active contributor to the Greek healthcare ecosystem by partnering with the scientific community, governmental organizations and patient advocacy groups in order to provide value to patients, healthcare professionals and health authorities.
About Daiichi Sankyo
Daiichi Sankyo is an innovative global healthcare company contributing to the sustainable development of society that discovers, develops and delivers new standards of care to enrich the quality of life around the world. With more than 120 years of experience, Daiichi Sankyo leverages its world-class science and technology to create new modalities and innovative medicines for people with cancer, cardiovascular and other diseases with high unmet medical need. For more information, please visit www.daiichi-sankyo.eu.
HQ/ONP/07/24/0007
| _______________________________ |
1 https://www.jto.org/article/S1556-0864(20)31099-6/fulltext |
To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.
View source version on businesswire.com: https://www.businesswire.com/news/home/20240709254444/en/
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Starr Completes Acquisition of IQUW Group23.3.2026 13:00:00 CET | Press release
Creates a stronger, more diversified global specialty platform Starr, a global investment and insurance organization, today announced that it has completed its acquisition of IQUW Group, creating a broader, more diversified specialty (re)insurance platform with enhanced capabilities across the London market, Bermuda and UK retail motor. The combined Starr business now serves more clients and brokers in more specialist classes and market segments globally. With IQUW Group, Starr has strengthened its position in the London market and established its managing agency as the ninth-largest at Lloyd’s. Importantly, Starr will continue to operate with a strong emphasis on underwriting expertise and best-in-class broker and client experience and service. Clients and brokers will benefit from a broader product offering, quick decision-making, greater capital strength and expanded global reach. Starr’s reinsurance capability is also significantly enhanced following this transaction. IQUW Re Bermu
Biocytogen Announces Strategic Collaboration with Moonlight Bio to Advance Cell Therapies Using Library of Antibody Binders23.3.2026 13:00:00 CET | Press release
Biocytogen Pharmaceuticals (Beijing) Co., Ltd. (Biocytogen, SSE: 688796; HKEX: 02315), a global biotechnology company that drives the research and development of novel antibody-based drugs with innovative technologies, today announced a strategic collaboration with Moonlight Bio, Inc., a Seattle-based biotech company pioneering advanced cell therapies. This partnership aims to develop cutting-edge cell therapies to address some of the most challenging and difficult-to-treat cancers. Dr. Yuelei Shen, President and CEO of Biocytogen, said, “We are thrilled to partner with Moonlight Bio, a pioneering leader in advanced cell therapies. This strategic collaboration leverages our proprietary off-the-shelf fully human antibody library to accelerate the development of cutting-edge cell therapies for difficult-to-treat cancers. It also demonstrates the versatility and broad applicability of Biocytogen’s antibody discovery platforms beyond traditional drug modalities. By combining our expertise,
Venture Global Launches First Advertising Campaign: “Unstoppable Energy”23.3.2026 11:30:00 CET | Press release
New ad campaign narrated by Academy Award winner Billy Bob Thornton will air nationally in the U.S. Today, Venture Global, Inc. (NYSE: VG) is launching its first national advertising campaign – “Unstoppable Energy”. The seven-figure, year-long campaign includes national and local broadcast television spots, as well as out-of-home, print, and digital ad placements. The company is proud to have Academy-Award winner Billy Bob Thornton as the campaign voiceover. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260323692879/en/ “Venture Global is excited to unveil our very first national advertising campaign, featuring the accomplished Billy Bob Thornton as its voice,” said Venture Global CEO Mike Sabel. “The Unstoppable Energy campaign portrays the roll-up-your-sleeves tenacity and innovation that drives our company every day. We are proud to introduce the ethos and story of the Venture Global brand across the U.S. as we grow into
Venture Global and Vitol Announce New LNG Purchase Agreement23.3.2026 11:00:00 CET | Press release
Today, Venture Global, Inc. (NYSE: VG) and Vitol announced the execution of a new, binding agreement for the purchase of approximately 1.5 million tonnes per annum (MTPA) of U.S. liquefied natural gas (LNG) from Venture Global for five years commencing in 2026, to be supplied from Venture Global’s portfolio. “Global demand for flexible, reliable U.S. LNG is rapidly growing, and Venture Global is proud to work with premier LNG trading companies like Vitol to provide this critical supply to the market,” said Venture Global CEO Mike Sabel. “Thanks to our innovative model, we have the ability to provide our customers with short, medium, and long-term LNG supply, and this agreement is another important step in diversifying the tenor of our LNG portfolio.” “Vitol is delighted to be working with Venture Global, a leading producer and supplier of LNG to world markets,” said Pablo Galante Escobar, Global Head of LNG at Vitol. “LNG is important to many economies worldwide. Through this transacti
RSA Launches ID Plus Sovereign Deployment: The Next Level of High Assurance Identity Security23.3.2026 11:00:00 CET | Press release
New “Deploy Anywhere” Solution Sets Industry Standard for Security, Availability, and Compliance Across Critical Sectors Today at RSAC Conference 2026, RSA, the security-first identity leader, announced the launch of RSA® ID Plus Sovereign Deployment, a groundbreaking evolution in high assurance identity solutions designed to meet the needs of organizations that must maintain constant availability, meet policy and data sovereignty laws, and defend themselves from advanced, persistent threats. RSA ID Plus Sovereign Deployment is the next evolution in RSA® ID Plus, the market’s most secure identity and access management (IAM) security platform featuring complete multi-factor authentication (MFA), SSO, and access capabilities. RSA ID Plus Sovereign Deployment features a new “deploy anywhere” capability that allows government agencies, financial services, critical infrastructure, and healthcare organizations to modernize their identity infrastructure while still maintaining the highest sta
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom